MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study to evaluate several intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Principal trial aims have been To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers, even though among the list https://ronx221oal6.yourkwikimage.com/user